Report Highlights
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Report Includes
- 44 data tables and 57 additional tables
- An update on the global market for cell and gene therapy tools and reagents
- Analyses of the global market trends, with historic market revenue for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- A look at the market potential for the cell and gene therapy tools and reagents in the life sciences industry, market drivers, and forecasts for the market segments of product, application, end user and region
- Facts and figures pertaining to major market dynamics, product innovations, clinical trials, and government regulations
- Review of the prevalence of infectious disease, metabolic disorders and chronic ailments, along with the recent technological advances, competitive landscape, and the industry value chain
- Coverage of the technological, economic and business considerations of the market, and the vendor landscape
- Analysis of the industry’s regulatory framework and policies, and product pipeline
- Discussion of ESG challenges and ESG practices in the industry
- Market share analysis of the key companies in the industry and coverage of their proprietary technologies and strategies
- Company profiles of major players within the industry, including Thermo Fisher Scientific Inc., Sartorius CellGenix GmbH, and Miltenyi Biotec
Report Scope
This report analyzes the global market for cell and gene therapy tools and reagents. The market is segmented by product type, disease or application, end user and region. Product types include gene vectors, GMP proteins, GMP antibodies, GMP small molecules, bioreactors, multiplex immunoassays, immunoassays, leukapheresis, cell separation, cell expansion, cytokine release syndrome monitoring, cryopreservation reagents, and solutions and media. Diseases or applications include cancer and rare diseases. End users include pharmaceutical and biotech companies, academic research institutes, and clinical laboratories. The regions covered are North America, Europe, Asia-Pacific and the Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.
This report also examines strategies and collaborations, discusses the regulatory landscape, and analyzes macroeconomic factors when considering new technologies, the industry's increasing competitiveness, and emerging customer needs. This report also examines analytical frameworks, such as ESG analysis, patent analysis, competitive analysis, and strategic recommendations, which will aid companies in devising their strategic plans.
Report Synopsis
| Report Metrics | Details | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2023 | ||||||||||||||
| Forecast period considered | 2024-2029 | ||||||||||||||
| Base year market size | $9.2 billion | ||||||||||||||
| Market size forecast | $16.7 billion | ||||||||||||||
| Growth rate | CAGR of 10.8% for the forecast period of 2024-2029 | ||||||||||||||
| Units considered | $ Millions | ||||||||||||||
| Segments covered | Product, Application, End User, Region | ||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World | ||||||||||||||
| Countries covered | U.S., Canada, Germany, France, U.K., Italy, Spain, Switzerland, Denmark, Norway, Poland, Belgium, Austria, Netherlands, Sweden, Russia, China, Japan, India, Australia, New Zealand, Taiwan, Singapore, Malaysia, Thailand, Philippines, Indonesia, Korea | ||||||||||||||
| Key Market Drivers |
|
||||||||||||||
| Companies studied |
|
Frequently Asked Questions (FAQs)
- Increasing investments in the field of cell and gene therapy research.
- Capacity expansion for clinical and commercial manufacturing.
- Increasing incidence of chronic diseases.
- A growing number of collaboration and acquisition strategies.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.
Report Includes
- 105 total tables
- An updated overview of the global market for immunoassay-based cell and gene therapy tools and reagents
- Analyses of the global market trends, with historic market revenue for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the market potential for the cell and gene therapy tools and reagents in the life sciences industry, growth driving factors, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of actual market size and revenue forecast for cell and gene therapy tools and reagents in USD million terms, and corresponding market share analysis based on product, application/disease area, end-user, and region
- In-depth information (facts and figures) concerning major market dynamics (DROs), product innovations, clinical trials, and various government regulations affecting the market outlook for cell and gene therapy tools and reagents
- Review of prevalence of infectious disease, metabolic disorders and chronic ailments; along with the recent technological advancements, competitive environment, and the industry value chain analysis
- Coverage of the technological, economic, and business considerations of the prevailing cell and gene therapy tools market, and its vendor landscape
- Patent review and new developments, R&D efforts, industrial changes with emphasis on recent investments, and current state of the immunoassay technology
- Identification of the companies best positioned to meet the demand for cell and gene therapy in life sciences applications owing to their proprietary technologies, novel product launches, key mergers and acquisition deals, and other strategic advantages
- Descriptive company profiles of the market leading players, including Abcam, Akron Biotech, Adverum Biotechnologies and Avrobio.
Report Highlights
The global market for life science tools should grow from $6.5 billion in 2019 to reach $9.0 billion by 2024 at a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2019-2024.
Report Includes
- 77 data tables
- An overview of the global market for immunoassay-based cell and gene therapy tools, and reagents within the life sciences industry
- Analyses of the global market trends, with data corresponding to market size for 2017-2019, and projections of compound annual growth rates (CAGRs) through 2024
- Information about in vitro diagnostics (IVD), its background and importance of IVD testing
- Discussion on prevalence of infectious disease, metabolic disorders and chronic ailments as drivers of immunoassay testing market
- Description of recent technologies such as chemiluminescent immunoassays (CLIA), fluorescent immunoassays, multiplex assays and rapid diagnostic technologies
- Evaluation of market potential for immunoassay-based cell and gene therapy tools and reagents, current market size and market forecast, and market share analysis of the leading players engaged
- Patent review and new developments, R&D efforts, industrial changes with emphasis on recent investments, and current state of the immunoassay technology
- Company profiles of the key market participants, including Bio-Rad Laboratories, Cytiva Life Sciences, Luminex Corp., Millipore Sigma, Thermo Fisher Scientific and STEMCELL Technologies
Related Reports
Induced Pluripotent Stem Cells: Global Markets
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Life Science Tools and Reagents: Global Markets
The global market for life science tools and reagents, including COVID-19 diagnostics was valued at $59.4 billion in 2023. This market is expected to grow from $53.2 billion in 2024 to reach $66.5 billion by the end of 2029, at a CAGR of 4.6% during the forecast period of 2024-2029.
Gene Synthesis: Technologies and Global Markets
The global market for Gene Synthesis is estimated to increase from $2.0 billion in 2023 to reach $4.1 billion by 2028, at a compound annual growth rate (CAGR) of 15.8% from 2023 through 2028.
Recent Reports
Global DNA Sequencing: Research, Applied and Clinical Markets
The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Induced Pluripotent Stem Cells: Global Markets
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More